AIM ImmunoTech (AIM) Stock Heads Up On Quarterly Results

AIM ImmunoTech AIM Stock News

AIM ImmunoTech Inc (NYSEAMERICAN: AIM) is headed up in the market this morning, trading on gains of more than 15% as it follows up on the recent activity that we’ve seen. The gains come after the company announced its most recent quarterly results. Here’s what’s happening:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

AIM Stock Pops On Quarterly Results

As is the case in any quarterly release, AIM ImmunoTech provided a look into its financials in the press release. However, that wasn’t what caused all of the excitement. The excitement seems to center around the company’s work in the COVID-19 space.

Nonetheless, in terms of finances, the company ended Q4 with cash, cash equivalents and marketable securities totalling up to $8.778 million, up from $1.825 million in Q4 ’18. Net loss from operations came in at $9.533 million, or $2.62 per share.

If finances were the only factor that investors were paying attention to, there would be a bit of concern here. After all, based on these numbers, the company is running dry on funding and a fund raise is likely around the corner.

Nonetheless, investors don’t seem to care that AIM may have to raise funds soon. They seem to be focused on the company’s work to develop Ampligen as a potential treatment for COVID-19 patients.

The largest section of the quarterly results release had to do with the company’s work in the coronavirus space. In the release, AIM reminded investors that it filed provisional patents, teamed up with NIID, ChinaGoAbroad, and others for the development and potential commercialization of Ampligen for COVID-19 patients.

The company also pointed to discussions that it is having with parties in Argentina to advance Ampligen for use against the coronavirus. The company is also in discussions to bring the candidate to the Netherlands.

The Bottom Line

The bottom line here is simple, investors aren’t too worried about AIM ImmunoTech’s financial blues because they know how profitable Ampligen could be if it proves to be effective in the fight against COVID-19.

Let’s face it, the coronavirus is changing life as we know it. As schools close, stores shut down, and global economies fall victim to the virus, demand for vaccines and treatments is only rising. Should the company’s Ampligen prove to be an effective treatment, AIM could see a tremendous revenue opportunity, which is the source of all of the excitement here.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.